Tomoko Narita

789 total citations
58 papers, 553 citations indexed

About

Tomoko Narita is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Tomoko Narita has authored 58 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 18 papers in Molecular Biology and 17 papers in Oncology. Recurrent topics in Tomoko Narita's work include Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (12 papers) and T-cell and Retrovirus Studies (11 papers). Tomoko Narita is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (12 papers) and T-cell and Retrovirus Studies (11 papers). Tomoko Narita collaborates with scholars based in Japan, Singapore and Germany. Tomoko Narita's co-authors include Shinsuke Iida, Masaki Ri, Takeshi Suzuki, Mitsuaki Yoshida, Shigeru Kusumoto, Hirokazu Komatsu, Asahi Ito, Takashi Ishida, Ayako Masaki and Shiori Kinoshita and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Tomoko Narita

52 papers receiving 551 citations

Peers

Countries citing papers authored by Tomoko Narita

Since Specialization

Citations

This map shows the geographic impact of Tomoko Narita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Narita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Narita more than expected).

Fields of papers citing papers by Tomoko Narita

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Narita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Narita. The network helps show where Tomoko Narita may publish in the future.

Co-authorship network of co-authors of Tomoko Narita

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Narita. A scholar is included among the top collaborators of Tomoko Narita based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Narita. Tomoko Narita is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunosuppressive Effects of Multiple Myeloma‐Derived Extracellular Vesicles Through T Cell Exhaustion 2025 ·Cancer Science ·(unknown), Masaki Ri, (unknown), (unknown), (unknown), (unknown), Takahiro Nakashima, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Hirokazu Komatsu, Shinsuke Iida	0
2	Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma 2025 ·Cancer Science ·(unknown), Masaki Ri, (unknown), Tomoyuki Nakamura, Hirokazu Sasaki, (unknown), Takahiro Nakashima, (unknown), Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Kazufumi Yamagata, Kohmei Kubo, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida	0
3	Prevalence of CCR7‐Positive CD8 T Cells as a Prognostic Factor in B‐Cell Maturation Antigen ‐Targeted Chimeric Antigen Receptor T Cell Therapy 2025 ·eJHaem ·(unknown), Masaki Ri, (unknown), (unknown), (unknown), Takahiro Nakashima, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Takaomi Sanda, Hirokazu Komatsu, Shinsuke Iida	0
4	Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma 2025 ·British Journal of Haematology ·Tomotaka Suzuki, (unknown), (unknown), Hirokazu Sasaki, (unknown), Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki	1
5	Comprehensive analysis of serum cytokines in patients with multiple myeloma before and after lenalidomide and dexamethasone 2024 ·Cancer Medicine ·(unknown), Masaki Ri, (unknown), Arisa Asano, (unknown), (unknown), Shiori Kinoshita, (unknown), Tomoko Narita, Ayako Masaki, Asahi Ito, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida	1
6	Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Tomotaka Suzuki, (unknown), (unknown), Aki Kondo, (unknown), (unknown), (unknown), (unknown), (unknown), Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida	2
7	The Impact of MYD88 and/or CD79B Gene Mutations on Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma 2024 ·Blood ·Tomotaka Suzuki, (unknown), (unknown), Hirokazu Sasaki, (unknown), Arisa Asano, Shiori Kinoshita, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Masaki Ri, Hirokazu Komatsu, (unknown), Hiroshi Inagaki	1
8	Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma 2023 ·International Journal of Hematology ·Yoko Nakanishi, (unknown), Masaki Ri, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida	4
9	Immunotherapy for ocular myasthenia gravis: an observational study in Japan 2023 ·Therapeutic Advances in Neurological Disorders ·Tomoko Narita, Shunya Nakane, Akiko Nagaishi, Naoya Minami, Masaaki Niino, Naoki Kawaguchi, Hiroyuki Murai, Jun‐ichi Kira, Jun Shimizu, Kazuo Iwasa, Hiroaki Yoshikawa, Yuki Hatanaka, Masahiro Sonoo, Yuko Shimizu, Hidenori Matsuo	2
10	Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients 2022 ·Hematological Oncology ·Arisa Asano, Masaki Ri, Ayako Masaki, Yasuhiro Maeda, (unknown), (unknown), (unknown), Takahiro Nakashima, (unknown), Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida	3
11	Very late onset neuromyelitis optica spectrum disorders 2021 ·European Journal of Neurology ·Keiichi Nakahara, Shunya Nakane, Akiko Nagaishi, Tomoko Narita, Hidenori Matsuo, Yukio Ando	11
12	Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma 2019 ·Cancer Science ·Takayuki Murase, Masaki Ri, Tomoko Narita, (unknown), Ayako Masaki, Shinsuke Iida, Hiroshi Inagaki	5
13	Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma 2019 ·International Journal of Hematology ·Takashi Yoshida, Masaki Ri, (unknown), (unknown), (unknown), (unknown), Hirokazu Sasaki, Shiori Kinoshita, (unknown), Tomoko Narita, Ayako Masaki, Asahi Ito, Shigeru Kusumoto, Takashi Ishida, Hirokazu Komatsu, Shinsuke Iida	5
14	Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma 2019 ·International Journal of Hematology ·(unknown), Masaki Ri, (unknown), Takashi Yoshida, (unknown), (unknown), (unknown), Shiori Kinoshita, Tomoko Narita, (unknown), Ayako Masaki, Asahi Ito, Shigeru Kusumoto, Hirokazu Komatsu, (unknown), (unknown), Shinsuke Iida	10
15	Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system 2019 ·Journal of Clinical and Experimental Hematopathology ·Takayuki Murase, Atsushi Inagaki, Ayako Masaki, (unknown), Tomoko Narita, Masaki Ri, Ichiro Hanamura, Shinsuke Iida, Hiroshi Inagaki	0
16	Human T‐cell lymphotropic/leukemia virus type 1 (HTLV‐1) Tax‐specific T‐cell exhaustion in HTLV‐1‐infected individuals 2018 ·Cancer Science ·Ayako Masaki, Takashi Ishida, Susumu Suzuki, Asahi Ito, Tomoko Narita, Shiori Kinoshita, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Ryuzo Ueda, Shinsuke Iida	23
17	Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma 2018 ·PLoS ONE ·Takashi Yoshida, Masaki Ri, Shiori Kinoshita, Tomoko Narita, (unknown), (unknown), Asahi Ito, Shigeru Kusumoto, Takashi Ishida, Hirokazu Komatsu, Shinsuke Iida	18
18	Clinical significance of tryptophan catabolism in Hodgkin lymphoma 2017 ·Cancer Science ·Ayako Masaki, Takashi Ishida, Yasuhiro Maeda, Asahi Ito, Susumu Suzuki, Tomoko Narita, Shiori Kinoshita, Hisashi Takino, Takashi Yoshida, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Hiroshi Inagaki, Ryuzo Ueda, Ilseung Choi, Youko Suehiro, Shinsuke Iida	22
19	Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma 2015 ·Clinical Cancer Research ·Ayako Masaki, Takashi Ishida, Yasuhiro Maeda, Susumu Suzuki, Asahi Ito, Hisashi Takino, (unknown), (unknown), Takashi Yoshida, Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Atsushi Inagaki, Hirokazu Komatsu, Akio Niimi, Ryuzo Ueda, Atae Utsunomiya, Hiroshi Inagaki, Shinsuke Iida	42
20	Down-regulation of the INK4 Family of Cyclin-Dependent Kinase Inhibitors by Tax Protein of HTLV-1 through Two Distinct Mechanisms 1999 ·Virology ·Takeshi Suzuki, Tomoko Narita, (unknown), Mitsuaki Yoshida	98

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact